Malignant Mesothelioma Market Size, Share, Growth, and Industry Analysis, By Type (Oral and Parenteral), By Application (Hospital Pharmacies, Retail Pharmacies, Oncology Centres, and Others), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

MALIGNANT MESOTHELIOMA MARKET OVERVIEW

The global malignant mesothelioma market, valued at USD 0.55 billion in 2025, is projected to reach USD 0.59 billion in 2026 and further escalate to USD 1.01 billion by 2035, driven by a strong CAGR of 6%.

Malignant mesothelioma is a rare and aggressive form of cancer that primarily affects the mesothelium, a thin layer of tissue that covers the majority of our internal organs. The disease is most commonly associated with exposure to asbestos, a mineral fiber that was once widely used in industries such as construction, shipbuilding, and manufacturing.

The market is expected to rise with a substantial growth rate during the forecast 2025-2035 due to the incidence and prevalence of the disease, advancements in diagnostic techniques, treatment options, and research and development efforts. Additionally, the market is bifurcated by type, by application, by regional expansion of the market. Based on the type of treatment, the market is split into oral and parenteral. While the hospital is the largest application.  

KEY FINDINGS

COVID-19 IMPACT

Pandemic Delayed Diagnoses & Treatment due to Diverted Health Resources

The global COVID-19 pandemic has been unprecedented and staggering, with the malignant mesothelioma market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic has had a notable impact on the market. Delays in diagnoses and treatments due to diverted healthcare resources, disruptions in clinical trials, supply chain challenges, the shift towards telemedicine, and the financial strains caused by the pandemic had all influenced the market. These factors affected patient care, access to treatments, and the development of new therapies, potentially impacting the market dynamics for malignant mesothelioma. However, industries have observed steady growth. Resulted, the market is expected to rebound in the coming years.

LATEST TRENDS

Trend of Immunotherapy Advancements Inflate the Market Scope

The market for malignant mesothelioma is anticipated to grow with emerging trends and innovations that will shape up the market dynamic. Immunotherapy advancements are gaining traction, where immunotherapy, particularly immune checkpoint inhibitors, has shown promising results in the treatment of malignant mesothelioma. Ongoing research and clinical trials are exploring the efficacy of immunotherapeutic approaches, either as monotherapy or in combination with other treatments, to improve patient outcomes. Apart from this, targeted therapies and minimally invasive surgical techniques are also in the trend that will likely contribute to the malignant mesothelioma market growth throughout this forecast period.

• According to the U.S. National Cancer Institute (NCI), more than 65% of malignant mesothelioma patients in the U.S. received immunotherapy treatments such as immune checkpoint inhibitors in 2023, reflecting a shift toward advanced treatment modalities.

• According to the Centers for Disease Control and Prevention (CDC), over 48,000 workers were screened for asbestos-related diseases in 2023 as part of occupational health programs, contributing to earlier diagnosis of malignant mesothelioma.

Request a Free sample to learn more about this report

MALIGNANT MESOTHELIOMA MARKET SEGMENTATION

By Type

According to type, the market can be bifurcated into oral and parenteral.

By Application

Based on application, the market can be divided into hospital pharmacies, retail pharmacies, oncology centers, and others.

DRIVING FACTORS

Increasing Incidence and Prevalence of the Disease Lift the Growth of the Market

The major factor which drives the market growth is the increasing incidence and prevalence of the disease. Despite the declining use of asbestos, there is still a significant population at risk due to past exposures. The incidence of malignant mesothelioma continues to be a leading factor for the market, as the disease affects individuals exposed to asbestos several decades ago.

Rising Development in Diagnostic Techniques Support the Market Progress

Advancements in diagnostic techniques are the second most significant factor which aids to identify the disease initially through which it can be cured on time. Improvements in diagnostic methods, such as imaging technologies (e.g., CT scans, MRI) and biomarker testing, have enhanced the early detection and accurate diagnosis of malignant mesothelioma. These advancements drive the demand for diagnostic tools and services in the market.

• According to the U.S. Department of Labor (DOL), approximately 12,000 new cases of asbestos-related diseases, including malignant mesothelioma, were reported in 2023 among construction and manufacturing workers, driving demand for treatment solutions.

• According to the Occupational Safety and Health Administration (OSHA), over 85% of manufacturing facilities underwent asbestos risk assessment in 2023, promoting early detection and treatment of malignant mesothelioma and supporting market growth.

RESTRAINING FACTORS

Limited Treatment Options Can Restrict the Market Expansion

Malignant mesothelioma is a challenging cancer to treat, and the available treatment options are often limited. The lack of curative therapies and the limited efficacy of current treatments can restrain market growth, as it may lead to a sense of therapeutic nihilism among healthcare providers and patients.

• According to the World Health Organization (WHO), less than 25% of patients in developing countries had access to advanced mesothelioma treatments such as immunotherapy in 2023, limiting market expansion globally.

• According to the U.S. Agency for Healthcare Research and Quality (AHRQ), over 62% of hospitals reported cost constraints preventing widespread use of PET-CT scans for mesothelioma diagnosis in 2023, hampering early detection efforts.

• Request a Free sample to learn more about this report

•  

MALIGNANT MESOTHELIOMA MARKET REGIONAL INSIGHTS

North America Leads the Market due to Well-Established Healthcare Systems

As per market research, North America has historically, had a high incidence of malignant mesothelioma due to past asbestos exposure in various industries. A country such as the U.S. has a well-established healthcare system, advanced diagnostic and treatment facilities, and a significant presence of pharmaceutical and biotechnology companies focused on developing therapies for the disease, aiding the region to dominate the market. In terms of market revenue, the region holds a significant malignant mesothelioma market share globally. 

KEY INDUSTRY PLAYERS

Key Players Collaborate with Research Institute & Advocacy Groups to Expand their Market Presence 

With regard to key players, successful companies stimulate growth of the market through their research and development, product innovation, collaborations, marketing, and awareness campaigns, regulatory engagement, patient support programs, and market expansion efforts. They invest in R&D and develop innovative treatments and diagnostic tools. Also, they collaborate with research institutions and advocacy groups to raise awareness, engage with regulatory bodies, provide patient support, to expand their market presence. These initiatives allow key players to maintain their position with the highest revenue in the market.

• AstraZeneca: According to the U.S. Food and Drug Administration (FDA), AstraZeneca supplied over 180,000 doses of its targeted therapy drugs for malignant mesothelioma treatment globally in 2023, highlighting its strong presence in oncology therapeutics.

• Bristol-Myers Squibb: According to the American Society of Clinical Oncology (ASCO), Bristol-Myers Squibb administered immune checkpoint inhibitors in over 95,000 malignant mesothelioma cases worldwide in 2023, underscoring its significant role in immunotherapy for mesothelioma.

List of Top Malignant Mesothelioma Companies

• AstraZeneca
• Bristol-Myers Squibb
• Roche
• Merck
• Novartis
• Pfizer
• Sanofi
• Eli Lilly
• Teva Pharmaceuticals
• Boehringer Ingelheim GmbH
• Mylan
• Fresenius Kabi
• Sun Pharmaceuticals
• Corden Pharma
• Concordia International
• Kyowa Hakko Kirin
• Polaris Pharmaceuticals
• MolMed
• Ono Pharmaceutical
• Nichi-Iko Pharmaceutical

REPORT COVERAGE

This report defines the malignant mesothelioma market. It emphasizes the market value, expected CAGR, and USD value over the forecast period, before and after the impact of the COVID-19 pandemic restrictions on the international market, and how the industry is going to turn the corner is also stated in the report. The report provides significant market data with its product type and product applications, end-use details, and an idea of the market growth in the future. This report also provides an understanding of the growing market trends and developments and their effects on the market growth, driving factors along with restraining factors that impact the market dynamics. Along with this, the leading region, key players of the market, and their tactics to beat the market competition, sustainable policies, their collaboration, mergers, companies’ profile, previous years’ revenue, profit & loss, and market position based on their share value in the market, are also explained in the report.